{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T12:17:58Z","timestamp":1744719478125},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00108-024-01754-8","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T22:01:43Z","timestamp":1723240903000},"page":"955-961","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bew\u00e4hrtes und Neues in der Arzneitherapie des Reizdarmsyndroms","The proven and the new in the pharmacotherapy of irritable bowel syndrome"],"prefix":"10.1007","volume":"65","author":[{"given":"Peter","family":"Layer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viola","family":"Andresen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,9]]},"reference":[{"issue":"12","key":"1754_CR1","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1055\/a-1591-4794","volume":"59","author":"P Layer","year":"2021","unstructured":"Layer\u00a0P, Andresen\u00a0V, Allescher\u00a0H, Bischoff\u00a0SC, Cla\u00dfen\u00a0M, Elsenbruch\u00a0S et\u00a0al (2021) Z\u00a0Gastroenterol 59(12):1323\u20131415","journal-title":"Z Gastroenterol"},{"issue":"9","key":"1754_CR2","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1016\/j.cgh.2021.12.005","volume":"20","author":"C Basnayake","year":"2022","unstructured":"Basnayake\u00a0C, Kamm\u00a0MA, Stanley\u00a0A, Wilson-O\u2019Brien\u00a0A, Burrell\u00a0K, Lees-Trinca\u00a0I et\u00a0al (2022) Long-Term Outcome of Multidisciplinary Versus Standard Gastroenterologist Care for Functional Gastrointestinal Disorders: A\u00a0Randomized Trial. Clin Gastroenterol Hepatol 20(9):2102\u20132111.e9","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"1754_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S2468-1253(19)30324-3","volume":"5","author":"CJ Black","year":"2020","unstructured":"Black\u00a0CJ, Yuan\u00a0Y, Selinger\u00a0CP, Camilleri\u00a0M, Quigley\u00a0EMM, Moayyedi\u00a0P et\u00a0al (2020) Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a\u00a0systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 5(2):117\u2013131","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"1754_CR4","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1111\/apt.17179","volume":"56","author":"MR Ingrosso","year":"2022","unstructured":"Ingrosso\u00a0MR, Ianiro\u00a0G, Nee\u00a0J, Lembo\u00a0AJ, Moayyedi\u00a0P, Black\u00a0CJ et\u00a0al (2022) Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome. Aliment Pharmacol Ther 56(6):932\u2013941","journal-title":"Aliment Pharmacol Ther"},{"key":"1754_CR5","doi-asserted-by":"publisher","first-page":"859967","DOI":"10.3389\/fcimb.2022.859967","volume":"12","author":"T Zhang","year":"2022","unstructured":"Zhang\u00a0T, Zhang\u00a0C, Zhang\u00a0J, Sun\u00a0F, Duan\u00a0L (2022) Efficacy of Probiotics for Irritable Bowel Syndrome: A\u00a0Systematic Review and Network Meta-Analysis. Front Cell Infect Microbiol 12:859967","journal-title":"Front Cell Infect Microbiol"},{"issue":"6","key":"1754_CR6","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/gutjnl-2021-325214","volume":"71","author":"CJ Black","year":"2022","unstructured":"Black\u00a0CJ, Staudacher\u00a0HM, Ford\u00a0AC (2022) Efficacy of a\u00a0low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. Gut 71(6):1117\u20131126","journal-title":"Gut"},{"issue":"8","key":"1754_CR7","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1136\/gutjnl-2020-321191","volume":"69","author":"CJ Black","year":"2020","unstructured":"Black\u00a0CJ, Thakur\u00a0ER, Houghton\u00a0LA, Quigley\u00a0EMM, Moayyedi\u00a0P, Ford\u00a0AC (2020) Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. Gut 69(8):1441\u20131451","journal-title":"Gut"},{"issue":"9","key":"1754_CR8","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/ajg.2013.197","volume":"108","author":"RW Chapman","year":"2013","unstructured":"Chapman\u00a0RW, Stanghellini\u00a0V, Geraint\u00a0M, Halphen\u00a0M (2013) Randomized clinical trial: macrogol\/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol 108(9):1508\u20131515","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"1754_CR9","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/apt.15001","volume":"48","author":"AC Ford","year":"2018","unstructured":"Ford\u00a0AC, Harris\u00a0LA, Lacy\u00a0BE, Quigley\u00a0EMM, Moayyedi\u00a0P (2018) Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther 48(10):1044\u20131060","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"1754_CR10","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/S2468-1253(20)30056-X","volume":"5","author":"V Andresen","year":"2020","unstructured":"Andresen\u00a0V, Gschossmann\u00a0J, Layer\u00a0P (2020) Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a\u00a0multicentre, randomised, double-blind, placebo-controlled clinical trial. Lancet Gastroenterol Hepatol 5(7):658\u2013666","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"1754_CR11","doi-asserted-by":"publisher","first-page":"e000287","DOI":"10.1136\/bmjgast-2019-000287","volume":"6","author":"CA Howell","year":"2019","unstructured":"Howell\u00a0CA, Markaryan\u00a0E, Allgar\u00a0V, Kemppinen\u00a0A, Khovanov\u00a0A, Pandya\u00a0P et\u00a0al (2019) Enterosgel for the treatment of adults with acute diarrhoea in a\u00a0primary care setting: a\u00a0randomised controlled trial. BMJ Open Gastroenterol 6(1):e287","journal-title":"BMJ Open Gastroenterol"},{"issue":"10414","key":"1754_CR12","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(23)01523-4","volume":"402","author":"AC Ford","year":"2023","unstructured":"Ford\u00a0AC, Wright-Hughes\u00a0A, Alderson\u00a0SL, Ow\u00a0PL, Ridd\u00a0MJ, Foy\u00a0R et\u00a0al (2023) Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a\u00a0randomised, double-blind, placebo-controlled, phase\u00a03\u00a0trial. Lancet 402(10414):1773\u20131785","journal-title":"Lancet"},{"issue":"4","key":"1754_CR13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/apt.15077","volume":"49","author":"YA Saito","year":"2019","unstructured":"Saito\u00a0YA, Almazar\u00a0AE, Tilkes\u00a0KE, Choung\u00a0RS, Van Norstrand\u00a0MD, Schleck\u00a0CD et\u00a0al (2019) Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome. Aliment Pharmacol Ther 49(4):389\u2013397","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"1754_CR14","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.clinthera.2023.01.010","volume":"45","author":"BE Lacy","year":"2023","unstructured":"Lacy\u00a0BE, Chang\u00a0L, Rao\u00a0SSC, Heimanson\u00a0Z, Sayuk\u00a0GS (2023) Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points. Clin Ther 45(3):198\u2013209","journal-title":"Clin Ther"},{"issue":"6","key":"1754_CR15","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1053\/j.gastro.2016.08.003","volume":"151","author":"A Lembo","year":"2016","unstructured":"Lembo\u00a0A, Pimentel\u00a0M, Rao\u00a0SS, Schoenfeld\u00a0P, Cash\u00a0B, Weinstock\u00a0LB et\u00a0al (2016) Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. Gastroenterology 151(6):1113\u20131121","journal-title":"Gastroenterology"},{"issue":"8","key":"1754_CR16","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1007\/s10620-016-4147-9","volume":"61","author":"M Camilleri","year":"2016","unstructured":"Camilleri\u00a0M, Piessevaux\u00a0H, Yiannakou\u00a0Y, Tack\u00a0J, Kerstens\u00a0R, Quigley\u00a0EMM et\u00a0al (2016) Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials. Dig Dis Sci 61(8):2357\u20132372","journal-title":"Dig Dis Sci"},{"issue":"4","key":"1754_CR17","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/nmo.12292","volume":"26","author":"DK Atluri","year":"2014","unstructured":"Atluri\u00a0DK, Chandar\u00a0AK, Bharucha\u00a0AE, Falck-Ytter\u00a0Y (2014) Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a\u00a0systematic review and meta-analysis. Neurogastroenterol Motil 26(4):499\u2013509","journal-title":"Neurogastroenterol Motil"},{"issue":"12","key":"1754_CR18","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1136\/gutjnl-2022-327293","volume":"71","author":"CA Howell","year":"2022","unstructured":"Howell\u00a0CA, Kemppinen\u00a0A, Allgar\u00a0V, Dodd\u00a0M, Knowles\u00a0CH, McLaughlin\u00a0J et\u00a0al (2022) Double-blinded randomised placebo controlled trial of enterosgel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D). Gut 71(12):2430\u20132438","journal-title":"Gut"},{"issue":"5","key":"1754_CR19","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.cgh.2007.12.015","volume":"6","author":"V Andresen","year":"2008","unstructured":"Andresen\u00a0V, Montori\u00a0VM, Keller\u00a0J, West\u00a0CP, Layer\u00a0P, Camilleri\u00a0M (2008) Effects of 5\u2011hydroxytryptamine (serotonin) type\u00a03 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a\u00a0systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 6(5):545\u2013555","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"1754_CR20","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1136\/gutjnl-2013-305989","volume":"63","author":"K Garsed","year":"2014","unstructured":"Garsed\u00a0K, Chernova\u00a0J, Hastings\u00a0M, Lam\u00a0C, Marciani\u00a0L, Singh\u00a0G et\u00a0al (2014) A\u00a0randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut 63(10):1617\u20131625","journal-title":"Gut"},{"key":"1754_CR21","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/S2468-1253(20)30215-6","volume":"5","author":"C Basnayake","year":"2020","unstructured":"Basnayake\u00a0C et\u00a0al (2020) Lancet Gastroenterol Hepatol 5:890\u2013889","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1754_CR22","first-page":"62","volume":"16","author":"I Zhang","year":"2016","unstructured":"Zhang\u00a0I et\u00a0al (2016) Biomed Chromatogr 16:62","journal-title":"Biomed Chromatogr"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01754-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-024-01754-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01754-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T13:03:55Z","timestamp":1724936635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-024-01754-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1754"],"URL":"https:\/\/doi.org\/10.1007\/s00108-024-01754-8","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"type":"print","value":"2731-7080"},{"type":"electronic","value":"2731-7099"}],"subject":[],"published":{"date-parts":[[2024,8,9]]},"assertion":[{"value":"4 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"P.\u00a0Layer und V.\u00a0Andresen geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}